NASDAQ:IONS

Ionis Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy IONS

*Your capital is at risk

$73.82

+0.85 (+1.16%)

At Close: Jun 03, 2026

Ionis Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -80.29. In total, the insiders bought 915.22K and sold 556.14K IONS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-80.29
● Buy	915.22K shares
● Sell	556.14K shares
66% Buy Activity Strong Negative Correlation
Sell Signal High Confidence Jan 16, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -80.29. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 16, 2026 Sell	Common Stock S-Sale	Baroldi Joseph EVP, Chief Business Officer	Officer	5 619 Value: $419.0K
Apr 16, 2026 Sell	Common Stock S-Sale	Birchler Brian EVP, Corp And Development Ops	Officer	973 Value: $73.0K
Apr 16, 2026 Sell	Common Stock S-Sale	Jenne Kyle EVP, Chf Gl Pdt Str Ofcr	Officer	4 902 Value: $368.5K
Apr 15, 2026 Buy	Restricted Stock Unit M-Exempt	Baroldi Joseph EVP, Chief Business Officer	Officer	10 837 Value: $832.5K
Apr 15, 2026 Buy	Common Stock M-Exempt	Baroldi Joseph EVP, Chief Business Officer	Officer	10 837 Value: $832.5K
Apr 15, 2026 Buy	Restricted Stock Unit M-Exempt	Birchler Brian EVP, Corp And Development Ops	Officer	1 875 Value: $144.0K
Apr 15, 2026 Buy	Common Stock M-Exempt	Birchler Brian EVP, Corp And Development Ops	Officer	1 875 Value: $144.0K
Apr 15, 2026 Buy	Common Stock M-Exempt	Jenne Kyle EVP, Chf Gl Pdt Str Ofcr	Officer	12 226 Value: $939.2K
Apr 15, 2026 Buy	Restricted Stock Unit M-Exempt	Jenne Kyle EVP, Chf Gl Pdt Str Ofcr	Officer	12 226 Value: $939.2K
Apr 15, 2026 Sell	Common Stock S-Sale	Parshall B Lynne Director	Director	534 Value: $41.1K
Apr 15, 2026 Sell	Common Stock S-Sale	Parshall B Lynne Director	Director	4 466 Value: $340.3K
Apr 02, 2026 Sell	Common Stock S-Sale	Devers Shannon L. EVP, Chief Human Resources Ofc	Officer	6 193 Value: $458.6K
Apr 01, 2026 Sell	Common Stock S-Sale	Klein Joseph Iii Director	Director	20 105 Value: $1.52M
Apr 01, 2026 Buy	Non-Qualified Stock Option (right to buy) M-Exempt	Klein Joseph Iii Director	Director	10 321 Value: $424.0K
Apr 01, 2026 Buy	Non-Qualified Stock Option (right to buy) M-Exempt	Klein Joseph Iii Director	Director	12 000 Value: $456.7K
Apr 01, 2026 Sell	Common Stock S-Sale	Klein Joseph Iii Director	Director	2 216 Value: $168.3K
Apr 01, 2026 Buy	Common Stock M-Exempt	Klein Joseph Iii Director	Director	12 000 Value: $456.7K
Apr 01, 2026 Buy	Common Stock M-Exempt	Klein Joseph Iii Director	Director	10 321 Value: $424.0K
Mar 19, 2026 Sell	Common Stock S-Sale	Schneider Eugene EVP, Chf Clinical Develop Ofcr	Officer	5 812 Value: $412.5K
Mar 17, 2026 Sell	Common Stock S-Sale	Hougen Elizabeth L EVP, Finance & CFO	C-Suite Officer	10 172 Value: $744.7K
Mar 16, 2026 Buy	Common Stock M-Exempt	Hougen Elizabeth L EVP, Finance & CFO	C-Suite Officer	20 541 Value: $771.9K
Mar 16, 2026 Buy	Common Stock M-Exempt	Hougen Elizabeth L EVP, Finance & CFO	C-Suite Officer	33 118 Value: $1.08M
Mar 16, 2026 Buy	Non-Qualified Stock Option (right to buy) M-Exempt	Hougen Elizabeth L EVP, Finance & CFO	C-Suite Officer	33 118 Value: $1.08M
Mar 16, 2026 Buy	Non-Qualified Stock Option (right to buy) M-Exempt	Hougen Elizabeth L EVP, Finance & CFO	C-Suite Officer	60 299 Value: $3.67M
Mar 16, 2026 Buy	Non-Qualified Stock Option (right to buy) M-Exempt	Hougen Elizabeth L EVP, Finance & CFO	C-Suite Officer	61 041 Value: $3.47M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IONIS PHARMACEUTICALS

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various...

Read Full Profile Here